Citations

Showing 10 of 108152 citations.

Growth Differentiation Factor-15, Treatment with Liraglutide, and Clinical Outcomes Among Patients with Heart Failure
Sharma, Abhinav , Greene, Stephen J. , Fudim, Marat , Ambrosy, Andrew P. , Sun, Jie‐Lena , McNulty, Steven E., Mentz, Robert J. , Felker, G. Michael , Mentz, Robert J , Vaduganathan, Muthiah , Hernandez, Adrian F. , Borlaug, Barry A. , Velazquez, Eric J. , DeVore, Adam D. , Alhanti, Brooke , Margulies, Kenneth B.

Mayo Clinic

ESC Heart Failure | June 1, 2021 | Volume: 8 | Issue: 4 | Pages: 2608-2616

10.1002/ehf2.13348 | PMID 34061470 Get It

Abstract Aims Associations between growth differentiation factor-15 (GDF-15), cardiovascular outcomes, and exercise capacity among patients with a recent hospitalization for heart failure (HHF) and heart failure with reduced ejection fraction (HFrEF) are unknown. We utilized data from the ‘Functional Impact of GLP-1 for Heart Failure Treatment’ (FIGHT) study to address these knowledge gaps. Methods and results FIGHT was a randomized clinical trial testing the effect of liraglutide (vs. placebo) among 300 participants with HFrEF and a recent HHF. Multivariable regression models evaluated associations between baseline GDF-15 and change in GDF-15 (per 1000 pg/mL increase from baseline to 30 days) with clinical outcomes (at 180 days) and declines in exercise capacity (6 min walk distance ≥ 45 m). At baseline (n = 249), median GDF-15 value was 3221 pg/mL (interquartile range 1938–5511 pg/mL). Participants in the highest tertile of baseline GDF-15 were more likely to be male and have more co-morbidities. After adjustment, an increase in GDF-15 over 30 days was associated with higher risk of death or HHF [hazard ratio 1.35, 95% confidence interval (CI) 1.11–1.64]. In addition, higher baseline GDF-15 (per 1000 pg/mL until 6000 pg/mL) and an increase in GDF-15 over 30 days were associated with declining 6 min walk distance (odds ratio 1.26, 95% CI 1.02–1.55 and odds ratio 1.37, 95% CI 1.12–1.69, respectively). GDF-15 levels remained stable among participants randomized to liraglutide. Conclusions An increase in GDF-15 over 30 days among patients in HFrEF was independently associated with an increased risk of cardiovascular events and declining exercise capacity. These results support the value of longitudinal GDF-15 trajectory in informing risk of heart failure disease progression.
Parental neurotic excoriation injury of children: A case series of hidden physical abuse
Hines, Larissa, Lang, Margaret E. , Johnson, Katie L. , Ruiz‐Maldonado, Tagrid M. , Feldman, Ken W., Graff, Arne H. , Hand, Jennifer L. , Feldman, Kenneth W.

Mayo Clinic

Pediatric Dermatology | June 1, 2021 | Volume: 38 | Issue: 4 | Pages: 859-863

10.1111/pde.14623 | PMID 34060140 Get It

AbstractBackgroundRecognizable skin findings of child physical abuse include bruises, abrasions, lacerations, bite marks, burns, and oral injuries. Self‐induced skin picking, or neurotic excoriation, can correspond to emotional stress, underlying psychiatric illness, or substance abuse. Parental neurotic excoriation injury of children has not been reported previously as a form of physical abuse.MethodsWe present a case series of five children abused via parental excoriation. All affected children were three years of age or younger and otherwise healthy. Each child presented with wounds determined to be consistent with chronic picking. Patient age, injury location, and in some cases, witness accounts confirmed the lesions were not self‐inflicted.ResultsIn three cases, caregivers reported methamphetamine use. In these cases, caregivers repeatedly picked or wiped the infants’ skin. In two cases, the caregiver demonstrated personal neurotic excoriation behavior, which was imposed upon her children resulting in similar lesions. One affected child died at 14 days of age from abusive head trauma, while the other four children were placed in foster care by Child Protective Services.ConclusionExcoriation injury places children at risk for significant scarring and other long‐term effects. We report examples demonstrating that repetitive skin injury by caregivers is a diagnostic consideration for abuse in young children.
A Window Into the Myofibrillar Myopathy Proteome
Liewluck, Teerin

Mayo Clinic

Neurology Genetics | June 1, 2021 | Volume: 7 | Issue: 3 | Pages: No page available

10.1212/nxg.0000000000000587 | PMID 34084941 Get It

Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 trial.
Chien, A. Jo , Ewing, Cheryl Ann, Campbell, Michael J. , Albain, Kathy S. , Stringer-Reasor, Erica , Church, An , Clark, Amy S. , Nanda, Rita, Berry, Donald A. , Soliman, Hatem Hussein , Boughey, Judy C. , Rugo, Hope S. , Wallace, Anne M. , Kalinsky, Kevin M. , Elias, Anthony , Mitri, Zahi Ibrahim , Thomas, Alexandra , Yau, Christina , Esserman, Laura J.

Mayo Clinic

Journal of Clinical Oncology | June 1, 2021 | Volume: 39 | Issue: 15_suppl | Pages: 508-508

10.1200/jco.2021.39.15_suppl.508 Get It

508 Background: I-SPY 2 is a multicenter, phase 2 trial using response-adaptive randomization within molecular subtypes defined by receptor status and MammaPrint (MP) risk to evaluate novel agents as neoadjuvant therapy for women with high-risk breast cancer. SD-101 is an investigational Toll-like receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide that stimulates the production of IFN-α and interleukin (IL)-12, functional maturation of plasmacytoid dendritic cells, and production of cytotoxic antibodies. IT SD-101 was combined with systemic anti-PD-1 antibody Pb to investigate the antitumor and immunologic activity of this novel immunotherapeutic strategy. Methods: Women with tumors ≥ 2.5cm were eligible for screening. Only pts (pts) with HER2- disease were eligible for this treatment. Treatment included weekly P x 12 in combination with IT SD-101 2 mg/ml (1 ml for T2 tumors, 2 ml for >T3 tumors) weekly x 4, then q3 weeks x 2, and IV Pb q3 weeks x 4, followed by doxorubicin/cyclophosphamide (AC) q2-3 weeks x 4 (SD-101+Pembro 4). Pts in the control arm received weekly P x 12 followed by AC q2-3 weeks x 4. The I-SPY 2 methods have been previously published. This investigational arm was eligible for graduation (>85% chance of success in a 300-person phase 3 neoadjuvant trial) in 3 of 10 pre-defined signatures: HER2-, hormone receptor (HR)+/HER2- and HR-/HER2-. Results: 75 pts were randomized and evaluable in SD-101+Pembro 4 treatment arm. The control arm included 329 historical controls enrolled since April 2010. The study arm was stopped due to maximal patient accrual. Pt characteristics were balanced; 56% HR+, 44% HR-. The probability that SD-101+Pembro4 was superior to control exceeded 97% for all eligible tumor signatures, but did not reach the threshold for graduation in any of the signatures. However, it is notable that the rate of pCR/Residual Cancer Burden 1 (RCB1) in the HR+/HER2- signature was 51%. Preliminary safety events for SD-101+Pembro 4 include increased rates of fever, neutropenia, febrile neutropenia, transaminitis, and immune-related events, including adrenal insufficiency. Conclusions: The SD-101+Pembro 4 regimen was active but did not meet the pre-specified threshold for graduation in I-SPY 2. pCR/RCB 1 analysis suggests improved response in the HR+/HER-negative signature compared to control. The clinical significance of these findings needs to be weighed against the potential risk of immune-related toxicities. Clinical trial information: NCT01042379. [Table: see text]
ATRT-04. CORRELATION OF CLINICOPATHOLOGIC FEATURES AND CUMULATIVE INCIDENCE OF RELAPSE FOR PATIENTS WITH ATYPICAL TERATOID RHABDOID TUMOR ON ACNS0333: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP
Reddy, Alyssa , Biegel, Jaclyn A. , Strother, Douglas, Judkins, Alexander R. , Pollack, Ian F. , Buxton, Allen, Mahajan, Anita , Ho, Ben, Mazewski, Claire , Lewis, Victor , Fouladi, Maryam , Krailo, Mark , Huang, Annie

Mayo Clinic

Neuro-Oncology | June 1, 2021 | Volume: 23 | Issue: Supplement_1 | Pages: i1-i1

10.1093/neuonc/noab090.003 Get It

Abstract Purpose Intensive multi-modal regimens have improved survival for patients with atypical teratoid rhabdoid tumor, however relapse rates remain high. A better understanding of clinical and pathologic features associated with tumor relapse is critical to risk-stratifying patients. Patients and Methods ACNS0333 treatment consisted of multi-agent chemotherapy, high-dose chemotherapy, and radiation therapy, lasting approximately 6 months. Variables including patient age, sex, tumor location, M-stage, degree of resection, order of therapy, germline status, and molecular subgroup were analyzed. Cumulative incidence (CI) of event free survival due to relapse was evaluated for each variable. Results Thirty-three of 65 evaluable patients had tumor relapse. For the entire cohort, the CI of relapse was 21.8% at 6 months, 40.6% at one year and 50.3% at 4 years. For patients with infratentorial tumors, CI of relapse was 26.3%, 34.2% and 37.2%, at 6 months, 1 and 4 years respectfully compared to 15.3%, 49.9%, and 69.7% for those with supratentorial tumors (p 0.051). Patients with SHH subtype had no relapses in the first 6 months and CI of relapse of 37.5% at 4 years, while those with TYR and MYC subgroups had CI of relapse of 33.3% and 26.7% at 6 months and 46.3% and 73.3% at 4 years respectfully (p 0.088). Patients with germline mutations had a cumulative incidence of relapse of 20% at 6 months and 60% at 12 months compared to 22.6% and 37.7% respectfully for those without. No obvious trends were noted based on other analyzed variables. Conclusions ACNS0333 was not powered to determine prognostic indicators of relapse, however, this data suggest interesting trends based on tumor location, subtype and germline status. Infratentorial location and SHH subtype maybe associated with lower risk of relapse. Larger data sets must be compiled to further investigate these variables, perform multivariate analyses and inform risk-stratification on future trials.
EMBR-03. PINEOBLASTOMA: A POOLED OUTCOME STUDY OF NORTH AMERICAN AND AUSTRALIAN THERAPEUTIC DATA
Huang, Jie , Li, Bryan , Gajjar, Amar , Endersby, Raelene , Wells, Olivia, Wray, Alison, Raleigh, David R. , Stoller, Schuyler , Mueller, Sabine , Bandopadhayay, Pratiti , Fouladi, Maryam , Onar, Arzu, Gottardo, Nicholas G. , Onar‐Thomas, Arzu , Hansford, Jordan R. , Dodgshun, Andrew , Hwang, Eugene , Leary, Sarah , Hoff, Katja von , Kotecha, Rishi S. , Schild, Steven E. , Bouffet, Éric , Huang, Annie

Mayo Clinic

Neuro-Oncology | June 1, 2021 | Volume: 23 | Issue: Supplement_1 | Pages: i6-i6

10.1093/neuonc/noab090.021 Get It

Abstract Background Pineoblastoma (PB) is a rare embryonal brain tumour most often diagnosed in young children. To date, no clinical trials have been conducted specific to pediatric PB. Collaborative studies performed over the past 30 years have included PB in studies accruing for other embryonal tumours, primarily medulloblastoma (MB), but also including the entity formerly known as CNS-PNET and atypical teratoid rhabdoid tumors. Each of these studies have included only a small number of children with PB, making clinical features difficult to interpret and determinants of outcome difficult to ascertain. Patients and Methods Published centrally reviewed series with sufficient treatment and outcome data from North American and Australian cases were pooled. To investigate associations between variables, Fisher’s exact and Wilcoxon-Mann-Whitney tests, and Spearman correlations were used as appropriate. Kaplan-Meier plots, log-rank tests, and Cox proportional hazards models were used in survival analysis. Results We describe a 30-year review of the reported clinical features of PB and a pooled centrally reviewed, cohort analysis of cases (n=178) from the Children’s Oncology Group (COG) (n=82) groups and several published, centrally reviewed institutional series (n=96). We find young children <3 years of age have a dramatically poorer outlook compared to older children (5-year OS 16.2% +/- 5.3% vs 67.3% +/- 5%) confirming new and novel approaches are needed in future clinical trials for this at risk group. Interestingly, male gender was predictive of worse outcome possibly suggestive of gender specific subgroup risks that needs validation in future studies. Assessment of radiation therapy is not possible as the vast majority of children under age three did not receive any form of radiation therapy. Conclusion Given the relative scarcity of this tumor and the emerging data on subgroups of pineoblastoma, prospective, collaborative international studies will be vital to improving the long-term survival of these patients.
Complement and Coagulation Cascades are Potentially Involved in Dopaminergic Neurodegeneration in α-Synuclein-Based Mouse Models of Parkinson’s Disease
Ma, Shi-Xun, Seo, Bo Am , Kim, Donghoon , Xiong, Yulan , Kwon, Seung‐Hwan , Brahmachari, Saurav , Kim, Sangjune , Kam, Tae‐In , Kwon, Sang Ho , Dawson, Ted M. , Pandey, Akhilesh , Na, Chan Hyun , Ko, Han Seok , Pandey, Akhilesh , Na, Chan Hyun , Kam, Tae-In , Nirujogi, Raja Sekhar , Dawson, Valina L.

Mayo Clinic

Journal of Proteome Research | June 1, 2021 | Volume: 20 | Issue: 7 | Pages: 3428-3443

10.1021/acs.jproteome.0c01002 | PMID 34061533 Get It

APOE Allele Testing and Alzheimer Disease—Reply
Choudhury, Parichita , Choudhury, Parichita , Ramanan, Vijay K. , Boeve, Bradley F.

Mayo Clinic

JAMA | June 1, 2021 | Volume: 325 | Issue: 21 | Pages: 2211

10.1001/jama.2021.4925 | PMID 34061147 Get It

Interaction Between APOE Genotype and Diabetes in Longevity
Shinohara, Mitsuru , Suzuki, Kaoru , Bu, Guojun , Sato, Naoyuki , Bu, Guojun

Mayo Clinic

Journal of Alzheimer's Disease | June 1, 2021 | Volume: 82 | Issue: 2 | Pages: 719-726

10.3233/jad-210125 | PMID 34092638 Get It

Background: While both apolipoprotein E (APOE) genotype and diabetes affect longevity as well as Alzheimer’s disease, their relationship remains to be elucidated. Objective: The current study investigated the potential interaction between diabetes and APOE for lifespan and their relationship with cognitive status. Methods: We reviewed the National Alzheimer’s Coordinating Center (NACC) dataset, which documents longitudinally clinical records of 24,967 individuals with APOE genotype and diabetic status. Results: Diabetes was associated with shorter lifespan in APOE3 carriers (n = 12,415, HR = 1.29, 95%CI = 1.17–1.42, p < 0.001) and APOE2 carriers (n = 2,390, HR = 1.37, 95%CI = 1.10–1.69, p = 0.016), while such associations were weaker and not significant in APOE4 carriers (n = 9,490, HR = 1.11, 95%CI = 0.99–1.24, p = 0.162). As there is a significant interactive effect of cognitive status and diabetes on lifespan (p < 0.001), we stratified subjects by cognitive status and observed persistent APOE-dependent harmful effects of diabetes in nondemented individuals but not demented individuals. Notably, questionnaire-based activity status, with which we previously observed an association between APOE genotype and longevity, was also significantly affected by diabetes only in non-APOE4 carriers. Conclusion: The effects of diabetes on longevity vary among APOE genotype. These effects are observed in nondemented individuals and are potentially associated with activity status during their lifespan.
Plasma Neurofilament Light and Future Declines in Cognition and Function in Alzheimer’s Disease in the FIT-AD Trial
Li, Danni , Zhang, Lin , Nelson, Nathaniel W. , Yu, Fang , Mielke, Michelle M.

Mayo Clinic

Journal of Alzheimer's Disease Reports | June 1, 2021 | Volume: 5 | Issue: 1 | Pages: 601-611

10.3233/adr-210302 | PMID 34514342 Get It

Background: Utilities of blood-based biomarkers in Alzheimer’s disease (AD) clinical trials remain unknown. Objective: To evaluate the ability of plasma neurofilament light chain (NfL) to predict future declines in cognition and activities of daily living (ADL) outcomes in 26 older adults with mild-to-moderate AD dementia from the FIT-AD Trial. Methods: Plasma NfL was measured at baseline and 3 and 6 months. Cognition and ADL were assessed using the AD Assessment Scale-Cognition (ADAS-Cog) and AD Uniform Dataset Instruments and Disability Assessment for Dementia (DAD), respectively, at baseline, 3, 6, 9, and 12 months. Linear mixed effects models were used to examine the associations between baseline or change in plasma NfL and changes in outcomes. Results: Higher baseline plasma NfL was associated with greater rate of decline in ADAS-Cog from baseline to 6 months (standardized estimate of 0.00462, p = 0.02853) and in ADL from baseline to 12 months (standardized estimate of –0.00284, p = 0.03338). Greater increase in plasma NfL in short term from baseline to 3 months was associated with greater rate of decline in memory and ADL from 3 to 6 months (standardized estimate of –0.04638 [0.003], p = 0.01635; standardized estimate of –0.03818, p = 0.0435) and greater rate of decline in ADL from 3 to 12 month (standardized estimate of –0.01492, p = 0.01082). Conclusion: This study demonstrated that plasma NfL might have the potential to predict cognitive and function decline up to 12 months. However, future studies with bigger sample sizes need to confirm the findings.